Mastercard (NYSE:MA) 2026 Conference Transcript
2026-11-11 05:25
Mastercard 2026年会议纪要关键要点总结 一、涉及公司与行业 - 纪要涉及公司为Mastercard(纽约证券交易所代码:MA),讨论焦点为其增值服务与解决方案(Value-Added Services and Solutions,简称VASS)业务[1][7] - 涉及行业包括支付网络、增值服务(咨询与洞察、安全与欺诈管理、身份验证、网络安全、持卡人互动与营销忠诚度)、代理式商务(Agentic Commerce)、人工智能在支付领域的应用[8][22][33] - 纪要提及的合作伙伴与客户包括Pinnacle Bank、Synovus、Evermore、Scotiabank、Yap Kredi等[55][56] - 纪要提及的收购标的包括Recorded Future(全球最大威胁情报公司)和BVNK[27][45] 二、核心观点与论据 (一)VASS业务规模与增长表现 - VASS目前占公司收入的40%,以高 teens(高百分之十几)的速度增长[8] - VASS业务中60%由网络驱动因素带动,形成"良性循环":数据越多,洞察越深,客户越愿意带来新业务,新业务又带来更多数据[14] - VASS整体业务的85%具有可重复性、可持续性和经常性特征,具备较强的可预测性[14] (二)VASS成功的原因与战略框架 - VASS战略围绕为客户交付价值与差异化展开,帮助客户解决复杂问题,被称为公司的"价值差异化器"和"价值乘数器"[8] - 服务业务从三个维度展开:一是洞察与能力(咨询、指导与洞察);二是安全(身份、欺诈管理及网络安全);三是持卡人互动(营销服务、奖励、忠诚度)[8] - 所有服务均由公司的交易数据、开放金融数据、实时支付数据驱动[8] - 各产品与解决方案之间的互操作性(interoperability)是独特性和差异化的关键来源,例如利用欺诈信号驱动个性化策略,或在咨询领域利用数据洞察[9][10] - 服务业务还用于帮助公司在核心支付业务上赢得净新业务[10] (三)竞争格局与竞争优势 - 竞争范围广泛:除传统网络竞争对手外,还与媒体公司、咨询公司、网络安全公司竞争[11] - 独特优势之一为 proprietary 数据:庞大、持续刷新、广泛且全球化,极少公司具备同等深度与广度的数据[11] - 独特优势之二为客户关系:发卡行侧数千家合作伙伴、商户侧、数字领域,均与网络连接,这些关系历经60年建立,难以复制[11] - 独特优势之三为跨不同轨道(实时支付RTP、开放金融)创新净新能力[12] - 三个层面的差异化难以被轻易复制[12] (四)增长算法(Growth Algorithm) - 增长算法具有持久性,有业绩结果支撑[14] - 第一维度:在已有客户中销售更多服务,触达其组织内新的采购中心,随着创新在不同用例、不同市场、不同采购中心持续扩展[15] - 第二维度:超越现有触达范围,与处理器、收单机构、聚合商、协会合作,以"一对多"方式将服务扩展至长尾商户、银行和处理器[15][16] - 第三维度:通过有机和无机方式(净新创新)将服务增长扩展至现有触达范围之外[16] - 三个维度结合支撑增长算法的可持续性[16] (五)周期性与宏观经济韧性 - 业务在地域上高度多元:覆盖210个国家和地区,极少出现210个国家和地区同时经历相同宏观经济状况的情形(COVID可能是唯一例外)[19] - 客户类型多元:银行、商户、金融科技公司、数字合作伙伴、政府[19] - 产品多元:从借记卡和预付卡到高端产品,服务的持卡人类型也高度多元[19] - 经济向好时,网络联动部分(占60%)受益;经济挑战时,产品与服务仍保持相关性,用例可能转移(如刺激组合、防欺诈、开发应时营销活动)[20] - 中东冲突案例:Mastercard Economics Institute为客户提供洞察,帮助区域内外的客户转向和导航[20][21] - 咨询能力与经济洞察在经济下行期价值更高,支撑服务业务穿越周期的持久性与韧性[21] (六)人工智能(AI) - AI被视为Mastercard及服务业务的顺风因素(tailwind)[22] - 内部应用:近100%的开发人员和编码人员使用AI工具,加快产品上市速度并确保创新与客户相关性[22] - 产品嵌入:服务能力中超过三分之一已嵌入AI,AI赋能服务的收入增速快于非AI赋能服务[22] - AI民主化了数据,也民主化了欺诈;公司帮助客户防欺诈的方式随AI演变[23] - Decision Intelligence Pro(DI Pro)案例:向商户和发卡行提供的风险评分能力,嵌入AI解决方案以更有效打击欺诈[23] - AI被视为绝对顺风,将继续在更多服务中嵌入AI[24] (七)网络安全与安全业务 - 安全是客户对话和董事会的核心议题[26] - 安全业务演进:从基础欺诈管理(交易合法性判断、批准或拦截决策)起步;哪怕一个百分点的批准率提升,也可能对合作伙伴的交易量、销售和收入产生重大变化[26] - 身份维度:利用生物识别等工具验证个人、企业或代理的合法性,需求持续增长[27] - 网络安全维度:随着AI普及,网络攻击也在增多;公司帮助客户预防攻击并在受害时指导应对[27] - 收购Recorded Future:全球最大威胁情报公司,将其威胁情报业务模式与公司支付洞察叠加,使输出对客户更有价值[27] - 欺诈、身份、网络三者结合极具价值,因为欺诈管理没有"一刀切"方案,客户通常需要多层防护方法[28] - Recorded Future能力迭代:推出第三方信任指标(third-party trust indicator),帮助客户判断第三方带入生态系统的风险并优先决策;还推出帮助商户和发卡行识别生态系统网络攻击风险的工具[28] - 安全是战略核心和增长算法的重要组成部分,随着欺诈者手段升级持续迭代用例[29] - Recorded Future在政府领域拥有重要客户基础,与全球超过十几个政府合作;政府日益成为公司客户,需要多层防护方法,视为"蛋糕扩大"的机会[30] (八)代理式商务(Agentic Commerce) - 代理式商务被视为Mastercard及服务业务的顺风因素,是数字商务的"下一次点击",是真实的机会,只是时间问题而非是否问题[33] - 支付层面推出Agent Pay:以透明方式为代理提供支付凭证访问权限;消费者、企业乃至机器可委托另一代理代为搜索和交易;交易代币化,公司从网络和服务两个层面受益[33] - 服务层面推出多项解决方案:Agent Connect(使商户对代理更可发现)、Agent Trust Indicator(让发卡行和商户对代理式交易风险评分)、Agent Suite(咨询层面,为客户提供注入公司安全、洞察、互动营销能力的Mastercard代理)[34] - 已在发卡和商户领域与合作伙伴达成多项咨询合作,帮助其用代理式解决方案解决复杂问题[35] - 在安全、洞察、互动及咨询各维度均深度布局代理式商务,视为网络的增长加速器[35] - 时间表:目前规模较小;历史支付演进均由消费者需求和企业需求驱动而非技术可用性;消费者和企业信任技术时才会起飞;Mastercard作为生态系统参与者居于网络中心,提供透明度、互操作性、规则、裁决,有助于建立信任并加速代理式商务[38][40][41] (九)定价策略 - 公司按价值定价(price for value),定价是与交付价值相称的持续评估过程,没有一刀切方案[42] - 定价具有多维度:客户基础多元、地域多元、实体多元、产品多元[42] - 公司持续投入数十亿美元于安全与安保,并寻求从交付的能力中提取价值[42] - Decision Intelligence Pro案例:去年因欺诈检测能力提升300%而纳入定价上调,认可其在交易认证与授权方面的价值[42] - 定价是持续进行的工作,将继续寻找机会[43] (十)并购(M&A)战略 - 并购采取高度纪律性的方法,评估标准包括:是否与战略相连、是否有权参与(right to play)、能否借助网络规模化目标公司业务模式、是否解决客户需求、是否提供与公司增长预期相称的长期可持续增长、以及经营杠杆[45] - 最新收购Recorded Future和BVNK均满足一项或多项标准,契合战略,具备规模化机会和超越现有触达范围的机会[45] - 并购活动与商业合作伙伴关系相辅相成,也与公司内部的有机开发与创新互补;三者结合驱动短期增长预期和长期创新预期[46] - 历史上大部分并购用于增强服务能力,尤其在洞察和安全安保领域,是成功的实践[47][50] (十一)服务业务在客户赢得中的作用 - Mastercard大多数客户关系都以某种形式嵌入服务,服务是价值乘数器和差异化方式,使公司能够服务客户整个企业而非仅支付领域[54] - 服务作为"开门器"(door opener):即使目标客户生态系统中没有公司的核心支付组合,也可通过洞察、安全或互动展示价值[54] - Pinnacle Bank案例:美国Pinnacle原为Mastercard客户,与Synovus(非Mastercard客户)合并后,客户乐于在服务领域合作,开发高端价值主张并协助组合转换,服务在决策中起关键作用[55] - Evermore案例:健康科技公司,帮助第三方向受益人分发福利,看重公司的欺诈能力及围绕福利分发创建欺诈参数、保护授权并减少损失的能力[56] - Scotiabank案例:将业务扩展至智利、乌拉圭和墨西哥等新市场,此前已在秘鲁和加勒比地区合作,看重公司的咨询能力和忠诚度能力,成为既有客户的开门器[56] - Yap Kredi案例(土耳其):上季度宣布的客户,正将业务转向公司,看重服务带来的益处[56] - 各维度均受益:扩展业务的既有客户、仅与竞争对手有合作经验的净新客户、以及新入市的全新项目,均因能获得跨多条业务线服务的单一合作伙伴而受益[57] (十二)创新方法论的演变 - 创新是"永远在线"(always-on)的活动,不是任何一个团队的职责,而是嵌入每个团队的设计思维心态[59] - 不仅思考当下,还思考商业的未来走向(where the puck is going)[59][60] - Start Path项目:与因AI或代理式商务而涌现的净新创新者或净新合作伙伴合作,指导现有客户确定合作落点、吸收其技术、建立商业伙伴关系,成为公司和服务增长的加速器[60] - Foundry团队:研究净新用例,在代理式商务成为热点之前就已思考,在联网设备商务还只是构想时就已布局[61] - 公司兼顾短期增长目标和长期模式可持续性及良性循环目标[61] - 公司在Linda任职期间及总体上拥有多种业务模式并从中受益[65] 三、其他重要但可能被忽略的内容 - Linda于1997年加入Mastercard,任职30年,历任多个领导岗位,包括投资者关系(IR)职能的创建、IPO参与,以及财务、合规、传播等公司职能;后半段职业生涯专注于客户关系管理,先后负责商户与收单机构、发卡行与金融科技公司、数字合作伙伴、政府[5] - Linda目前领导Mastercard的增值服务业务[1] - 会议主持人Sanjay与Linda相识20年,正值公司IPO时期,Sanjay是首批覆盖该股票的分析师之一[5] - 公司IPO距今20年[5] - 公司数据来源包括交易数据、开放金融数据、实时支付数据[8] - 公司业务覆盖210个国家和地区[19] - 公司服务客户类型包括银行、商户、金融科技公司、数字合作伙伴、政府[19] - 公司投入数十亿美元于安全与安保领域[42] - Recorded Future与全球超过十几个政府合作[30] - 公司通过Start Path项目和Foundry团队布局净新创新与未来用例[60][61]
Celcuity (NasdaqCM:CELC) FY Conference Transcript
2026-11-11 05:02
Celcuity (NasdaqCM:CELC) FY Conference November 10, 2026 03:00 PM ET Speaker0 Okay. Let's get started with our next fireside with Celcuity. My name is Rosy Liao. I am a member of the biotech research team here at Guggenheim Securities. With me, I have Brian Sullivan, CEO and co-founder of Celcuity. Welcome. Great to have you here. Speaker1 Thank you. My pleasure. Speaker0 To get started, maybe for those who are less familiar with the story, could you provide a quick overview of the company, a high-level vie ...
Phathom Pharmaceuticals (NasdaqGS:PHAT) FY Conference Transcript
2026-11-11 05:02
Phathom Pharmaceuticals (NasdaqGS:PHAT) FY Conference November 10, 2026 03:00 PM ET Speaker0 Hello, everyone. This is Yatin Suneja, one of the biotech analysts at Guggenheim. It is my pleasure to welcome Steven Basta, who is the President and Chief Executive Officer of Phathom. We will be chatting with him on all things happening at Phathom. Steven, thank you so much. Always a pleasure to chat with you and have you here at our conference. Why don't you make some opening comments, maybe review for us the thi ...
Jade Biosciences (NasdaqCM:JBIO) FY Conference Transcript
2026-11-11 05:00
Jade Biosciences (NasdaqCM:JBIO) FY Conference November 10, 2026 03:00 PM ET Okay. That's a great overview, so thanks for that. Why don't we dive into 101 first, and then I'll have Arseniy jump in more on 201 and 301. Before we get to 101 and kind of the progress you've made there, obviously a lot of developments in the IgAN space more broadly, so maybe you can just talk about how you see this IgAN marketplace sort of evolving going forward, and then we'll talk about the place 101 might have in there. Speak ...
BlossomHill Therapeutics (NasdaqGS:BLSM) FY Conference Transcript
2026-11-11 05:00
BlossomHill Therapeutics (NasdaqGS:BLSM) FY Conference November 10, 2026 03:00 PM ET Speaker0 Welcome to this next fireside chat with BlossomHill Therapeutics. With us today, we have Jean Cui, President and CEO, as well as Geoff Oxnard, Chief Medical Officer. Jean and Geoff, welcome. Thanks for joining us today. Thanks. For those investors who are meeting BlossomHill for the first time, what is the idea behind your macrocyclic design approach, Jean, and how does the team's experience in building Turning Poi ...
AdaptHealth (NasdaqCM:AHCO) Conference Transcript
2026-11-11 04:47
AdaptHealth (NasdaqCM:AHCO) Conference November 10, 2026 02:45 PM ET Speaker0 Good afternoon, everybody. Welcome day two, UBS Global Healthcare Conference. I am Kevin Caliendo, UBS Healthcare IT and Distribution Analyst, and we are very proud and happy today to have with us management team from AdaptHealth, and featuring Suzanne Foster, the CEO. Suzanne, thank you so much for joining us again this year. Maybe before we start, you want to give a quick sort of overview of the last quarter or anything else you ...
Xylem (NYSE:XYL) 2026 Conference Transcript
2026-11-11 04:45
Speaker0 Appreciate it. Xylem (NYSE:XYL) 2026 Conference November 10, 2026 02:45 PM ET Speaker0 and we're pleased to welcome the Xylem management team with us today. Matthew Pine, CEO, Andrea van der Berg, CFO, Greg Giometti, IR. We got a full slate here today. We're going to dive right into Q&A. If you've got any questions, please raise your hand or send me an email. Cards in front of you have the address. I'll be happy to integrate those questions into the conversation here. But thanks for coming. Speaker ...
Biodesix (NasdaqGM:BDSX) Conference Transcript
2026-11-11 04:45
Biodesix (NasdaqGM:BDSX) Conference November 10, 2026 02:45 PM ET Speaker0 All right. Good afternoon. My name is Doug Schenkel. On behalf of UBS, it is my pleasure to welcome Robyn Cowie, Chief Financial Officer, and Tim Dupont, Head of Sales Operations and Project Manager, as well as leader for digital diagnostic development at Biodesix. Thanks to the two of you for joining us this afternoon. Speaker1 Thanks for having us. Speaker2 It is our pleasure, Doug. Thanks. Speaker0 So, over the next half hour, the ...
Aura Biosciences (NasdaqGM:AURA) 2026 Conference Transcript
2026-11-11 04:42
In my experience, the more things you are trying to do at the same time, the more execution suffers a little bit. If you want to be the best in the world, you kind of have to go all in on it. We announced preliminary data from the NMIBC program in the summer. It actually looked quite encouraging, which provides a nice read-through into the ocular oncology space. We decided to put that program, finish the study, but deprioritize it and go all in on building the world's preeminent ocular oncology company arou ...
Kestra Medical Technologies (NasdaqGS:KMTS) FY Conference Transcript
2026-11-11 04:42
Kestra Medical Technologies (NasdaqGS:KMTS) FY Conference November 10, 2026 02:40 PM ET Speaker0 Good afternoon. Welcome to the Wolfe Healthcare Conference. My name is Mike Polark, medical device analyst here at Wolfe Research. Pleased in this session to be joined by Kestra Medical CEO Brian Webster, CFO Vaseem Mahboob. Brian and Vaseem, welcome. Thanks for being here. Speaker1 Thanks, Mike. Speaker0 Brian, I'll pass it to you to set the stage, and then we can jump into some Q&A. Maybe reflect on the last 1 ...